Wockhardt becomes India's first to get regulatory nod for novel antibiotics

摘要

The DCGI has approved EMROK (IV) and EMROK 0 (Oral), two new antibiotics from Wockhardt, the Mumbai-based pharmaceutical company. The milestone approval set Wockhardt s the country's first to get the nod from the regulatory authority. The medicine has been developed for the treatment of acute bacterial skin and skin structure infections, including diabetic foot infections and concurrent bacteraemia.